|
Conesa-Zamora P, Ruiz-Cosano J, Torres-Moreno D, Español I, Gutiérrez-Meca MD, Trujillo-Santos J, Pérez-Ceballos E, González-Conejero R, Corral J, Vicente V, Pérez-Guillermo M. Polymorphisms in xenobiotic metabolizing genes (EPHX1, NQO1 and PON1) in lymphoma susceptibility: a case control study. BMC Cancer. 2013 May 7;13:228. doi: 10.1186/1471-2407-13-228. PubMed PMID: 23651475; PubMed Central PMCID: PMC3649938.
AÑO: 2013; IF: 3.319
|
23651475
|
Ruiz-Cosano J, Conesa-Zamora P, González-Conejero R, Pérez-Ceballos E, Martínez-Francés A, Vicente V, Pérez-Guillermo M. Role of GSTT1 and M1 null genotypes as risk factors for B-cell lymphoma: influence of geographical factors and occupational exposure. Mol Carcinog. 2012 Jun;51(6):508-13. doi: 10.1002/mc.20814. Epub 2011 Jun 16. PubMed PMID: 21681823.
AÑO: 2012; IF: 4.269
|
|
Sancho JM, Orfao A, Quijano S, García O, Panizo C, Pérez-Ceballos E, Deben G, Salar A, González-Barca E, Alonso N, García-Vela JA, Capote J, Peñalver FJ, Provencio M, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM; Spanish Group for the Study of CNS Disease in NHL. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol. 2010 Oct;85(4):321-8. doi: 10.1111/j.1600-0609.2010.01478.x. Epub 2010 Jul 28. PubMed PMID: 20528905.
AÑO: 2010; IF: 2.785
|
|
Bosch F, Ferrer A, Villamor N, González M, Briones J, González-Barca E, Abella E, Gardella S, Escoda L, Pérez-Ceballos E, Asensi A, Sayas MJ, Font L, Altés A, Muntañola A, Bertazzoni P, Rozman M, Aymerich M, Giné E, Montserrat E. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res. 2008 Jan 1;14(1):155-61. doi: 10.1158/1078-0432.CCR-07-1371. PubMed PMID: 18172266.
AÑO: 2008; IF: 6.488
|
|
Hernández-Espinosa D, Miñano A, Martínez C, Ordoñez A, Pérez-Ceballos E, de Arriba F, Mota RA, Ferrer F, González M, Vicente V, Corral J. Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. Lab Invest. 2008 Mar;88(3):306-17. doi: 10.1038/labinvest.3700717. Epub 2008 Jan 14. PubMed PMID: 18195690.
AÑO: 2008; IF: 4.58
|